The invention pertains to new aminophthalazine compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds that are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.
[EN] The invention pertains to new aminophthalazine compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds that are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom. [FR] La présente invention concerne des composés d'aminophthalazine qui servent d'inhibiteurs effectifs de phosphodestérase (PDE). L'invention a aussi trait aux composés qui sont des inhibiteurs sélectifs de PDE-10. Elle concerne aussi des intermédiaires de préparation de tels composés, les compositions pharmaceutiques comprenant de tels composés et l'utilisation de tels composés dans des procédés de traitement de certains systèmes nerveux centraux (CNS) ou autres troubles. Cette invention a aussi trait à des procédés de traitement de troubles neurodégénératifs et psychiatriques, par exemple la psychose et les troubles comprenant des troubles cognitifs comme symptôme.